Prime Drugs Profile
Key Indicators
- Authorised Capital ₹ 9.51 M
as on 06-12-2024
- Paid Up Capital ₹ 9.50 M
as on 06-12-2024
- Company Age 30 Year, 22 Days
- Last Filing with ROC 31 Mar 2024
- Revenue -7.36%
(FY 2022)
- Profit -43.82%
(FY 2022)
- Ebitda -58.19%
(FY 2022)
- Net Worth 2.76%
(FY 2022)
- Total Assets 2.22%
(FY 2022)
About Prime Drugs
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 9.51 M and a paid-up capital of Rs 9.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sarat Parsan and Suchitra Parsan serve as directors at the Company.
- CIN/LLPIN
U24232WB1994PTC066190
- Company No.
066190
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Nov 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Prime Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sarat Parsan  | Director | 01-Apr-2000 | Current |
| Suchitra Parsan | Director | 01-Aug-1998 | Current |
Financial Performance and Corporate Structure Insights of Prime Drugs.
Prime Drugs Pvt Ltd, for the financial year ended 2022, experienced Minor drop in revenue, with a 7.36% decrease. The company also saw a substantial fall in profitability, with a 43.82% decrease in profit. The company's net worth moved up by a moderate rise of 2.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prime Drugs?
In 2020, Prime Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Parsan Brothers And Beverages Private LimitedActive 27 years 6 months
Sarat Parsan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prime Drugs?
Unlock and access historical data on people associated with Prime Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prime Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prime Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
